Congenital central hypoventilation syndrome.

Area of Science:

• Genetics
• Neuroscience
• Respiratory Medicine

Background:

• Congenital central hypoventilation syndrome (CCHS) is a disorder affecting autonomic control of breathing, primarily during sleep.
• CCHS is predominantly caused by de novo PHOX2B gene mutations, often polyalanine repeat expansions.
• Understanding the pathophysiological mechanisms of CCHS is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the role of PHOX2B gene mutations in the pathophysiology of CCHS using mouse models.
• To elucidate the impact of PHOX2B mutations on respiratory control and the retrotrapezoid nucleus (RTN).
• To explore potential therapeutic strategies for CCHS based on cellular responses to mutated PHOX2B.

Main Methods:

• Generation and analysis of genetically engineered mice, including Phox2b(27Ala/+) knock-in and conditional knock-out models.
• Physiological and neuroanatomical studies to assess breathing patterns, ventilatory responses, and RTN development.
• In vitro analyses of cellular responses to polyalanine-expanded Phox2b aggregates.

Main Results:

• Phox2b(27Ala/+) knock-in mice exhibited severe respiratory deficits, including apneas, lack of hypercapnia response, and early death, with absence of the RTN.
• Conditional mouse mutants with targeted Phox2b(27Ala) expression in the RTN showed initial lack of hypercapnia response but survived to adulthood with partial recovery.
• Cellular studies identified toxic effects of polyAla Phox2b aggregates, suggesting potential pharmacological targets.

Conclusions:

• PHOX2B mutations, particularly polyalanine expansions, are central to CCHS pathophysiology, affecting RTN development and respiratory control.
• Mouse models effectively recapitulate key features of CCHS, providing valuable tools for studying the disease.
• Emerging research on cellular mechanisms and potential therapeutic agents like desogestrel offers hope for CCHS treatment.